Normosang (Human Hemin)

Human Hemin provides an external source of heme that feeds back to inhibit hepatic aminolevulinic acid synthase (ALAS), the key enzyme driving porphyrin synthesis. This inhibition lowers the production of aminolevulinic acid and porphobilinogen, preventing the buildup of neurotoxic compounds responsible for acute porphyria episodes.

The dosage of Normosang is individualized and determined by the prescribing clinician based on the severity of the porphyria attack, patient weight, and clinical response. Healthcare professionals calculate the appropriate amount and infusion schedule for each patient.

Safety data for Human Hemin in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it must be prescribed and monitored by a qualified healthcare provider.

To place an order, submit an enquiry on the Normosang product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

The primary alternative to Normosang is heme arginate (Panhematin). Both are heme analogues that suppress ALAS activity, but formulation differences exist: Normosang is supplied as a lyophilized powder for reconstitution, while heme arginate is a ready‑to‑use solution. Clinical efficacy is comparable, and choice often depends on local availability, handling preferences and regulatory status.

Normosang must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to infusion, the lyophilized powder is reconstituted with the appropriate diluent under aseptic conditions.

Normosang is administered intravenously. After reconstitution, the solution is infused over a period specified by the treating physician, typically ranging from 30 minutes to several hours, depending on the clinical situation and patient tolerance.

Serious adverse events include hypersensitivity reactions such as anaphylaxis, acute hemolysis in patients with glucose‑6‑phosphate dehydrogenase deficiency, and renal impairment or acute kidney injury. Prompt recognition and management of these reactions are essential during and after infusion.

Normosang is contraindicated in individuals with known hypersensitivity to human hemin or any of its excipients. It should also be avoided in patients with G6PD deficiency due to the risk of hemolysis, and in those where the risk of severe allergic reaction outweighs the therapeutic benefit.